Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.51 |
| ▸ | GABRE | P78334 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651545 | 1.00 | MIF (0.61) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL30586191 | 0.88 | PTPN1 (0.54) | MIFSMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL29651755 | 0.88 | PTPN1 (0.54) | MIFSMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL4366639 | 0.83 | KDM4E (0.73) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2853275 | 0.83 | NPC1 (0.64) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL21253091 | 0.83 | NPC1 (0.64) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| Isoflavone SCHEMBL31264756 | 0.82 | ALDH1A1 (0.66) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| Isoflavone SCHEMBL8028 | 0.82 | ALDH1A1 (0.66) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| Isoflavone SCHEMBL6290885 | 0.82 | ALDH1A1 (0.66) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 | |
| Isoflavone SCHEMBL6542422 | 0.82 | ALDH1A1 (0.66) | MIFMAOBSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2024-05-02 | — | — | US | claimed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| WO-2022171121-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | 同润生物医药(上海)有限公司 | 2022-08-18 | — | — | WO | claimed |
| EP-2914343-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG Therapeutics Inc. (US) | 2015-09-09 | — | — | EP | claimed |
| WO-2014071125-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | claimed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | claimed |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023123742-A1 | SEMI-FUMARATE CRYSTAL OF PI3Kδ/γ DUAL INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR | 同润生物医药(上海)有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2022171121-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | 同润生物医药(上海)有限公司 | 2022-08-18 | — | — | WO | disclosed |
| EP-3004106-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-04-13 | — | — | EP | disclosed |
| EP-2916868-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | Rhizen Pharmaceuticals S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010042933-A9 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010042933-A2 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009049214-A2 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | MIF 368/4885MAOB 4250/4885SMN1; SMN2 4576/4885 |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | MIF 574/4885MAOB 2694/4885SMN1; SMN2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.